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Abstract
Background: Some low molecular weight heparins (LMWHs) prolong survival of cancer patients and inhibit experimental 
metastasis. The underlying mechanisms are still not clear but it has been suggested that LMWHs (at least in part) limit 
metastasis by preventing cancer cell-induced destruction of the endothelial glycocalyx.
M ethodology/Principal Findings: To prove or refute this hypothesis, we determined the net effects of the endothelial 
glycocalyx in cancer cell extravasation and we assessed the anti-metastatic effect of a clinically used LMWH in the presence 
and absence of an intact endothelial glycocalyx. We show that both exogenous enzymatic degradation as well as 
endogenous genetic modification of the endothelial glycocalyx decreased pulmonary tumor formation in a murine 
experimental metastasis model. Moreover, LMWH administration significantly reduced the number of pulmonary tumor foci 
and thus experimental metastasis both in the presence or absence of an intact endothelial glycocalyx.
Conclusions: In summary, this paper shows that the net effect of the endothelial glycocalyx enhances experimental 
metastasis and that a LMWH does not limit experimental metastasis by a process involving the endothelial glycocalyx.
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Introduction
In experimental animal models and clinical studies it has been 
well established that some low molecular weight heparins 
(LMWH) inhibit experimental metastasis and prolong survival 
[1,2]. Although the underlying mechanisms are only partially 
understood, it has been suggested that the endothelial glycocalyx 
may play an important role in the life prolonging effects of 
LMWH in patients.
The endothelial glycocalyx is a negatively charged, organized 
network of membranous glycoproteins, proteoglycans and glycos- 
aminoglycans that affects several biological processes with 
potential importance for cancer cell extravasation. First, the 
endothelial glycocalyx is essential for vascular barrier function. Its 
disruption by pro-inflammatory cytokines, including tumor 
necrosis factor (TNF-a) and glycocalyx-degrading enzymes such 
as heparanase and hyaluronidase, leads to increased vascular 
permeability [3-5]. Second, the glycocalyx has anticoagulant 
properties and thrombin generation is reduced by the glycocalyx 
because it stores various natural anticoagulant factors such as 
antithrombin, protein C and tissue factor pathway inhibitor [6].
Consequently, disruption of the endothelial glycocalyx instantly 
results in thrombin generation and platelet adhesion [7]. Third, 
through its diversity in biochemical make-up, the endothelial 
glycocalyx both prevents and facilitates cell adhesion to the 
endothelium. The size of the glycocalyx (predominantly its 
heparan sulphate proteoglycan and hyaluronate composition) 
exceeds the size of the adhesion molecules (syndecan-1, L- and P- 
selectin), thereby masking these proteins and preventing adhesion 
of among others leukocytes [8]. On the other hand, when 
glycocalyx bound components such as hyaluronic acid are released 
they may serve as ligands for the CD44 receptor expressed on 
many cells (including cancer cells). The glycocalyx thus plays an 
important role in cell adhesion to the vessel wall [9,10]. Fourth, 
the glycocalyx binds growth factors and extracellular matrix 
components via its proteoglycan syndecan-1. Moreover, syndecan- 
1 modulates fibroblast growth factor-2 (FGF-2) and vascular 
endothelial growth factor (VEGF) activity [11]. The glycocalyx is a 
sink of growth factors that in general are anti-apoptotic and of 
VEGF that can increase endothelial permeability [12]. Overall, 
the endothelial glycocalyx may thus be an important player in 
several biological processes with potential relevance for cancer cell
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metastasis. The relative importance of the particular pro- and anti­
metastatic effects of the endothelial glycocalyx in vivo remains to be 
elucidated however.
Interestingly, cancer cells produce enzymes that are known to 
degrade the endothelial glycocalyx, such as heparanase and 
hyaluronidase [12-16]. These enzymes consequently influence 
vascular endothelial barrier integrity, adhesive properties of the 
endothelial lining, cytokine production and can liberate heparan 
sulfate-bound growth factors thereby inducing cancer cell extrav­
asation. As heparin, LMWHs and heparin derivatives can abolish 
the activity or binding of heparanase [17,18] and hyaluronidase
[19] by competing with heparan sulphates and hyaluronan [20-22], 
it has been hypothesized that LMWHs (at least in part) limit cancer 
progression by restoring cancer cell-induced glycocalyx damage 
thereby limiting cancer cell extravasation [23].
In the current manuscript, we aimed to assess whether the effect 
of a LMWH on experimental metastasis depends on restoration of 
the endothelial glycocalyx. To this end, we first determined the net 
effect of the endothelial glycocalyx in experimental metastasis. 
Next, we assessed the effect of a LMWH in the presence or 
absence of an intact endothelial glycocalyx to determine the 
contribution of the glycocalyx to the effect of this LMWH on the 
reduction of experimental metastasis.
Results and Discussion
To assess the net effect of the endothelial glycocalyx on 
experimental metastasis, wild type mice were treated with 
hyaluronidase in order to remove hyaluronan and, in part, 
heparan sulphates from the endothelial glycocalyx. As it has 
previously been shown that one hour after hyaluronidase 
treatment vascular leakage is evident [4], B16F10 melanoma cells 
were injected intravenously 1h after intravenous hyaluronidase or 
saline administration. Experimental metastases in the lung were 
examined 14 days later. As shown in Figure 1, the number of 
pulmonary tumor foci was significantly reduced by approximately 
30% after hyaluronidase treatment as compared to the saline 
injected control group. Enzymatic degradation of the glycocalyx 
(at least of its hyaluronan component) thus limits experimental
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Figure 1. Effect of hyaluronidase on the number of B16F10 
pulmonary tumor foci. C57BI/6 mice were treated intravenously with 
100U hyaluronidase 1h prior to the administration of 3.5x105 B16F10 
melanoma cells into the lateral tail vein. Mice were sacrificed 14 days after 
cancer cell injection and the number of tumor foci at the surface of the 
lungs was determined. Error bars represent means ±  SEM (n = 8); *, p<0.05. 
doi:10.1371/journal.pone.0011200.g001
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metastasis suggesting that the net effect of the glycocalyx is pro­
metastatic. These data imply that hyaluronidase-induced endo­
thelial barrier disruption and consequent increased vascular 
permeability that would promote cancer cell extravasation is 
counteracted by the loss of specific adhesion molecules and/or 
growth factors from the glycocalyx. However, it should be realized 
that hyaluronidase treatment may not only destroy the endothelial 
glycocalyx but may also trigger the immune system which would 
reduce the number of cancer cells in the circulation [24,25]. 
Furthermore, hyaluronidase increases circulating levels of hyalur- 
onan oligomers which are known to limit cancer progression [10]. 
In addition, one could argue that systemic hyaluronidase 
treatment may also target the glycocalyx of cancer cells and this 
might be particularly relevant because impairment of the 
glycocalyx makes the cancer cell vulnerable to the immune system 
[26]. However, circulating hyaluronidase levels at the moment of 
cancer cell inoculation are rather low due to the short half-life of 
hyaluronidase (i.e. 2.7 minutes in rat plasma [27], resulting in a 
circulating level of below 0.0001 U) suggesting that the observed 
effect is not dependent on destruction of the cancer cell glycocalyx.
To confirm the pro-metastatic effect of the glycocalyx and to 
exclude ‘‘side effects’’ like acute immunological responses [24,25] 
and/or increased hyaluronan oligomers of hyaluronidase treatment 
that may also be responsible for the observed reduction in cancer cell 
extravasation, we assessed the effect of a genetically impaired 
glycocalyx on cancer cell extravasation. To this end, syndecan-1 
deficient mice were subjected to the experimental metastasis model. 
Lack ofthis endothelial glycocalyx proteoglycan disturbs the structure 
of the glycocalyx by reducing the amount of heparan sulphate 
moieties. As proteoglycans bidirectionally influence their signaling 
pathways, it might be expected that the reduced content of heparan 
sulphate moieties is accompanied by a reduction in hyaluronan 
content. As shown in Figure 2, when injected intravenously with 
B16F10 melanoma cells these syndecan-1 deficient mice showed a 3­
fold reduced number of pulmonary tumor foci compared to wild type 
mice. These data show that genetic disruption of heparan sulphate 
moieties of the glycocalyx is anti-metastatic as well.
As already indicated, the glycocalyx is considered as an integrated 
and balanced carbohydrate layer in which both hyaluronan and 
heparan sulfate chains are key structural components. Importantly, 
our data show that targeting either hyaluronan (enzymatically by 
hyaluronidase treatment) or the heparan sulphate chains (genetic 
ablation of syndecan-1) of the glycocalyx leads to reduced 
experimental metastasis. As these two different interventions have 
a similar effect on experimental metastasis, our data imply that 
barrier protective-properties of the glycocalyx are less essential for 
metastasis than its functions in cancer cell adhesion or growth factor 
storage [28]. Future experiments are needed however to fully 
appreciate the role of specific components of the glycocalyx on 
metastasis and to elucidate the underlying mechanisms.
As mentioned before, some LMWHs protect against cancer 
progression in experimental animal models and clinical trails, 
including the B16F10 melanoma model of experimental metastasis. 
As suggested previously, these LMWHs may inhibit metastasis 
through competitive binding of heparanase or hyaluronidase 
thereby protecting the vascular endothelium and its barrier function 
from disruption caused by these enzymes. To assess whether the 
inhibitory effect of the administration of a LMWH on cancer 
progression are dependent on its protective effects on the glycocalyx, 
we compared the effect of enoxaparin administration on experi­
mental metastasis in syndecan-1 deficient and wild type mice. As 
shown in Figure 2, enoxaparin injected intravenously at 30 min 
prior, and 6 and 12 h after cancer cell inoculation decreased the 
number of pulmonary tumor foci in wild type mice almost
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Figure 2. Pulmonary tumor foci formation in syndencan-1 —I— 
versus wild type mice with and without treatment with LMWH.
Syndecan-1 —/— and wild type mice were administered 2.0x105 B16F10 
melanoma cells into the lateral tail vein. One group of mice was treated 
with LMWH (15 mg/kg enoxaparin ) prior to the administration of B16F10 
melanoma cells and LMWH treatment was repeated after 6,12 and 24 h. 
Mice were sacrificed 14 days after cancer cell injection and the number of 
tumor foci at the surface of the lungs was determined. Error bars 
represent medians ±  interquartile range (n = 8), * p<0.05; *** p<0.001. 
doi:10.1371/journal.pone.0011200.g002
completely. Interestingly, LMWH administration also effectively 
reduced pulmonary tumor foci formation in syndecan-1 deficient 
animals (p = 0.02). These data show that the effect of this particular 
LMWH on secondary tumor formation is syndecan-1 independent 
and suggest that the cancer inhibiting effect of LMWHs may not be 
mediated by restoration of glycocalyx barrier function.
Some aspects of the experimental set-up require further 
comments. First, a lower amount of cancer cells was injected in 
the second experiment (Figure 2) in order to achieve lower numbers 
of pulmonary tumor foci that could be assessed more easily. 
Consequently, the wild type mice had less pulmonary tumor foci 
than in Figure 1. Moreover, syndecan-1-deficient mice appeared to 
be even better protected to secondary tumor formation than mice 
which received a single dose of hyaluronidase (approximately 80% 
versus 33% reduction in tumor foci in syndecan-1 deficient and 
hyaluronidase treated mice, respectively). This may imply that long 
term irreversible glycocalyx damage is more protective than 
temporally enzyme-mediated glycocalyx damage.
In conclusion, our data show that targeted interference of either 
hyaluronan or heparan sulfate limits experimental metastasis 
suggesting that the net effect of the glycocalyx is pro-metastatic. 
Moreover, the effect of enoxaparin on cancer progression and 
cancer cell metastasis is glycocalyx independent.
Materials and Methods
Hyaluronidase and heparin
Bovine testicular hyaluronidase (type IV-S; Sigma-Aldrich, St. 
Louis, MO) dissolved in 0.9% NaCl was administered intrave­
nously in a dose of 100 units per mouse 1h prior to cancer cell 
inoculation [4]. LMWH (15 mg/kg; enoxaparin, Sanofi-Aventis, 
Paris, France) was injected 30 min prior to and 6, 12 and 24 h 
after cancer cell inoculation.
Cells and cell culture
Murine B16F10 melanoma cells were obtained from the 
American Type Culture Collection (ATCC; Manassas, VA). Cells 
were cultured in Dulbecco Modified Eagle Medium (DMEM; 
Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum 
(Sigma-Aldrich), 1% penicillin-streptomycin solution and 1% L- 
glutamine at 37°C as described before [29,30]. Single cell 
suspensions were prepared from 2 mM EDTA-treated monolay­
er’s which were washed and diluted in phosphate-buffered saline 
(PBS) prior to counting and inoculation. Cells were stored on ice 
until administration.
Animals
Eight to ten week-old C57Bl/6 male mice (Charles River, 
Maastricht, The Netherlands) were maintained at the animal care 
facility of the Academic Medical Centre, Amsterdam, The 
Netherlands according to institutional guidelines. Syndecan-1 
—/  — male mice on a C57Bl/6 background were housed and bred 
in the Radboud University Nijmegen Medical Centre and handled 
as described [31-34]. Animal procedures were carried out in 
compliance with Institutional Standards for Humane Care and 
Use of Laboratory Animals. The institutional Animal Care and 
Use Committee approved all experiments (protocol number 
DIX101092).
Experimental pulmonary metastasis model
Cancer cells (suspended in 200 ml PBS) were injected into the 
lateral tail vein as described before [35-37]. In the first experiment, 
3.5 x105 cancer cells were administered per mouse, whereas in the 
second experiment 2.0 x105 cells were used in order to lower the 
amount of secondary tumor foci for purpose of countability. After
14 days, mice were sacrificed and lungs were prepared as described 
before [30]. Secondary tumor formation on the surface of the lungs 
was counted macroscopically in a blinded fashion with respect to the 
intervention. Experiments were performed with 8 mice per group.
Statistical analysis
Statistical analysis was carried out in GraphPad Prism version
4.03. Data are expressed as means + / — SEM or medians with 
interquartile range. For normally distributed data, significance was 
assessed with the Student t-test. For not normally distributed data, 
non-parametric testing was performed using the Mann-Whitney test. 
Statistical significance was assumed when the p-value was <0.05.
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